SEAPORT THERAPEUTICS INC (SPTX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$20.39-2.72%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · SPTX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -55.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 116 industry peers · Company calendar date is not available
SPTX — earnings miss
Dated 2026-08-03
Results of Operations and Financial Condition. On August 3, 2026, Seaport Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended June 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Section 1…
Why it matters: The test checks whether people can drive safely the morning after taking GlyphAllo. A clear safety signal may ease a key use concern.
Supportive ifAbout nine hours after dosing, the Phase 1 trial finds no clear drop in simulated driving performance.
Worry ifAbout nine hours after dosing, the trial finds a clear drop in simulated driving performance.
Why it matters: This Phase 2b trial tests GlyphAllo in major depression. Its results are a key test of the lead program.
Watch forBUOY-1 meets its main study goal, with a clear benefit over placebo on depression symptoms.
Also watch forBUOY-1 misses its main study goal or shows no clear benefit over placebo on depression symptoms.
Why it matters: Starting the trial would move GlyphAgo into testing in people with anxiety and sleep problems. A delay would push back a key test of the drug.
Supportive ifSeaport starts the Phase 2a trial in people with GAD and sleep disturbance by December 31, 2026.
Worry ifSeaport has not started the Phase 2a trial by December 31, 2026, or reports a delay.
Why it matters: A start would advance the program into a larger test of GlyphAgo in generalized anxiety disorder. A delay would put the stated timeline at risk.
Supportive ifSeaport starts the Phase 2b trial in people with GAD by June 30, 2027.
Worry ifSeaport has not started the Phase 2b trial by June 30, 2027, or reports a delay.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$290 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $722 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,224 loss on $10,000 · 42.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Seaport has no reported revenue and is funding clinical trials from its cash balance. A shorter runway could limit how far it can advance its programs.
Worry ifA new company update still says cash, cash equivalents, and investments can fund current plans into 2029.
Less concerning ifA company update moves the cash runway before 2029 or says added funding is needed sooner.